Skip to content Skip to footer

Dassault Systèmes to Acquire ArisGlobal for ~$2B

Shots: Dassault Systèmes has entered into a definitive agreement to acquire ArisGlobal, creating the industry’s first unified intelligence platform As per the deal, Dassault will acquire ArisGlobal for ~$1.8B at closing in cash & ~$200M in additional payments linked to multi-year AI-related revenue milestones; closing is expected in H2’26 Acquisition will advance Dassault Systèmes’ ambition to…

Read more

Insilico Medicine and Bora Pharmaceuticals Form AI-Driven Alliance with Potential Value Exceeding $2.5B

Shots: Insilico has entered into a multi-target strategic alliance with Bora to combine its Pharma.AI platform with Bora's expertise in drug development, manufacturing, quality, & commercialization Insilico will provide end-to-end AI solutions and R&D strategies to accelerate Bora’s AI- & automation-driven drug discovery & development, with plans to expand AI across development planning, process optimization,…

Read more

Viz.ai Partners with Cortechs.ai to Expand AI Platform into Neurodegenerative Disease Care

Shots: Viz.ai has partnered with Cortechs.ai to integrate its NeuroQuant & NeuroQuant MS into its AI-powered care coordination platform, expanding into neurodegenerative diseases The collaboration will initially focus on multiple sclerosis by integrating Cortechs.ai’s quantitative MRI analysis into Viz.ai’s clinical workflow & care coordination platform to improve MS identification, characterization, & management The company plans…

Read more

Longeviti Launches ClearFit AI Platform for Bedside Brain Ultrasound Access

Shots: Longeviti Neuro has launched ClearFit AI, a Brain Ultrasound Interface, creating a persistent acoustic window to the brain to enable real-time bedside ultrasound imaging after neurosurgery ClearFit AI combines sonolucent cranial implants, ultrasound compatibility, clinical workflow support, & AI-enhanced imaging to enable bedside brain assessment within existing neuro care workflows, potentially reducing CT/MRI transport…

Read more

Sanyou Biopharmaceutical and Baiyunshan Xihe Partner on AI-Driven Radiopharmaceutical Development

Shots: Sanyou & Baiyunshan Xihe have entered into a strategic collaboration to co-develop novel radiopharmaceuticals & radiodiagnostic products by combining AI-driven drug discovery with nuclear medicine expertise As per the deal, Sanyou Bio will contribute its AI-STAL libraries & AI-Drug Accelerator platform for target molecule discovery, while Baiyunshan Xihe will lead radionuclide production, radiolabeling, preclinical…

Read more

Median Technologies Receives CE Mark for eyonis LCS to Detect and Diagnose Lung Cancer

Shots: Median Technologies has received CE Mark for eyonis Lung Cancer Screening (LCS) to detect & diagnose lung cancer In testing eyonis LCS has showed 93.3% sensitivity & 92.4% specificity, with 68% reduction of False Positives & 66% reduction of False Negatives, minimizing unnecessary follow-ups eyonis Lung Cancer Screening is an AI-powered computer-aided detection & diagnosis…

Read more

Insilico Medicine Collaborates with Takeda to Advance AI Drug Discovery

Shots: Insilico Medicine has entered into a strategic collaboration agreement with Takeda to advance clinically differentiated drug candidates across Takeda's therapeutic areas, using Insilico’s Pharma.AI platform Insilico will lead AI-driven discovery, while Takeda will advance selected candidates through clinical development & hold exclusive worldwide rights to develop, manufacture, & commercialize resulting therapeutics As per the…

Read more

Boulevard Bio Inks ~$1.62B Licensing Deal with METiS TechBio for MTS-128

Shots: METiS TechBio has granted Boulevard worldwide development, manufacturing, and commercialization rights to MTS-128, a trispecific T-cell engager (TCE) program As per the deal, METiS TechBio will receive a $20M upfront payment & ~$1.6B in development, regulatory, & commercial milestone payments, in addition to tiered royalties on product sales MTS-128 is a trispecific T-cell engager…

Read more